ASX announcements

Date Title
22/01/2014 Regeneus partners with Lonza for manufacturing CryoShot Canine cell therapy product for US FDA trial
06/03/2014 Publication of Kvax cancer vaccine paper shows safety and efficacy in animals
21/03/2014 Regeneus to present at Regenerative Medicine Investor Day March 26 in New York
26/03/2014 Osteoarthritis treatment, HiQCell, shows continuing significant patient improvements at 12 months post-treatment and beyond
04/04/2014 Regeneus partners with US specialist manufacturer for its canine cancer immunotherapy
08/04/2014 Regeneus receives ethics approval for collecting stem cells from human donors for first-in-man safety trial of its off-the-shelf treatment for osteoarthritis
14/05/2014 Regeneus stem cells show promise as new treatment option for sufferers of chronic neuropathic pain
30/06/2014 Regeneus enters into US marketing trial agreement for novel canine cancer vaccine
08/07/2014 Regeneus secures exclusive worldwide rights for new therapeutic human cancer vaccine
31/07/2014 Product Pipeline Update
08/08/2014 Regeneus to raise capital through share Placement and SPP to accelerate new product developments
15/08/2014 Regeneus successfully closes $3M private placement
15/08/2014 Notification under section 708A(5)(e) of the Corporations Act 2001 (Cth)
19/08/2014 Osteoarthritis cell therapy, HiQCell, shows continuing significant patient improvements at 2 years post-treatment
19/08/2014 Share Purchase Plan (SPP)
21/08/2014 Regeneus and Cryosite partner for the development and manufacture of human stem cell products
27/08/2014 AFL approves use of Regeneus’ stem cell therapy, HiQCell for injured players
09/09/2014 Regeneus Share Purchase Plan closes oversubscribed
11/09/2014 Kvax canine cancer treatment now available to Australian dog owners, US marketing trial starts
23/09/2014 Regeneus’ osteoarthritis cell therapy, HiQCell, to launch in Singapore, under leading sports physician, Dr Patrick Goh
25/09/2014 Regeneus receives R&D tax incentive refund of $3.7m
25/09/2014 Notice of Annual General Meeting 28th Oct 2014 and Explanatory Statement
09/10/2014 Response to ABC 7:30 Report Media Commentary
28/10/2014 Presentation to Shareholders at AGM 2014
28/10/2014 Regeneus Annual General Meeting Address by Executive Chairman John Martin
28/10/2014 Results of 2014 Regeneus Annual General Meeting
10/11/2014 Board and Management Changes
14/11/2014 Acne Treatment Patent Granted
24/11/2014 Regeneus sets platform for next phase of development
26/11/2014 New regenerative medicine laws to fast track cell therapy approvals take effect in Japan
19/12/2014 Patent granted for protecting cryopreserved stem cells